- Exelixis reported an EPS of 65 cents for the second quarter, surpassing the estimate of 57 cents but falling short compared to last year’s 77 cents.
- Total revenue came in at $568.3 million, a decline of 11% compared to the previous year and below the estimated $578.5 million.
- Net product revenues rose by 19% year-over-year, totaling $520.0 million, slightly under the estimate of $526.9 million.
- Total operating expenses were $354.7 million, showing a decrease of 1.8% year-over-year, and fell below the estimated $376.3 million.
- Research & Development expenses were reduced by 5.1% year-over-year to $200.4 million, also under the estimate of $231.2 million.
- The company decided not to advance to the phase 3 portion of the STELLAR-305 trial due to emerging competition and potential larger commercial opportunities elsewhere.
- Analyst ratings include 11 buys, 9 holds, and 1 sell recommendation.
Exelixis Inc on Smartkarma
Analyst coverage of Exelixis Inc on Smartkarma indicates positive sentiment towards the company’s recent financial performance and pipeline expansion. Baptista Research published two research reports on Exelixis Inc, with a bullish outlook on the company’s growth prospects.
In one report titled “Exelixis Inc.: Will It Be Able To Build On the XB628 & Other Pipeline Expansion Opportunities?”, Exelixis demonstrated strong financial performance in the first quarter of 2025, with significant growth in cabozantinib net product revenue. Another report by Baptista Research titled “Exelixis Inc.: Pipeline Expansion & Innovation to Build A Robust Portfolio!” highlighted the company’s robust performance in fiscal year 2024, driven by the strong performance of the cabozantinib franchise and ongoing developments in the oncology portfolio. These analyses provide investors with valuable insights into Exelixis Inc‘s potential for future growth.
A look at Exelixis Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Exelixis Inc, a development-stage biotechnology company focussed on creating small-molecule therapeutics for cancer and other diseases, shows a promising long-term outlook. With strong scores in Growth, Resilience, and Momentum, the company is positioned for future success. Its Growth and Resilience scores indicate a positive trajectory in developing effective pharmaceutical products, while the high Momentum score suggests a current strong performance trend within the industry.
However, the company’s Value and Dividend scores indicate areas for potential improvement. Despite this, the overall outlook for Exelixis Inc seems bright, with a solid foundation for future growth and innovation based on its Smartkarma Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
